Repligen Lines Up $1 Billion Of 0.25% Convertible Notes, Swapping Out Part Of Its 2028 Debt
The notes due 2031 convert at about $226.37 a share, and Repligen will use $120.0 million of the cash raised to buy back its own stock.
Repligen, which makes filtration, chromatography and other products that drugmakers use to manufacture biologic drugs, agreed to issue $1.0 billion of 0.25% convertible notes due 2031, using part of the deal to retire older 1.00% notes due 2028, according to an 8-K filed Friday. The agreements were dated October 29.
Half swap, half cash
About $541.4 million of the new notes will go to holders of the 2028 notes in exchange for about $456.8 million of those older notes. Another $458.6 million of new notes will be sold for cash to new investors, the company said in its press release. Repligen gets no cash from the exchanged portion.
After closing, $143.2 million of the 2028 notes will remain outstanding on unchanged terms.
The new notes pay interest of 0.25% a year, semiannually starting May 1, 2027, and mature November 1, 2031 unless converted, redeemed or repurchased earlier.
A $226.37 conversion price
Holders can convert the notes at an initial price of about $226.37 a share, roughly a 20% premium to the $188.64 last reported sale price on October 29. Repligen can settle conversions in cash up to the principal amount, then in cash, shares or a mix for anything above it. At the maximum conversion rate, up to 5,301,100 shares could be issued.
Repligen can redeem the notes for cash on or after November 6, 2029 if its stock has traded at 130% or more of the conversion price for at least 20 trading days in a 30-day stretch.
Buyback and use of proceeds
Repligen plans to spend about $120.0 million of the cash proceeds buying its shares from certain note purchasers at $188.64. The rest is earmarked for working capital and general corporate purposes, including possible acquisitions. The placement agent, J. Wood Capital Advisors, intends to buy about $30.0 million of the stock from deal participants at a discount to that price. The company warned that both purchases could lift the share price or the notes' price.
Chief Financial Officer Jason Garland said the deals "proactively address the upcoming maturity of our 2028 Notes" and cut interest expense. He said the lower interest cost is expected to be nominally accretive to adjusted earnings per share in 2026, with more benefit expected in 2027. Near term, he said, the company is focused on integrating BioLife.
The transactions are expected to close on or about November 6.
Sources
- 8-K Filing — REPLIGEN CORP (RGEN) — SEC EDGAR
- Exhibit rgen-20261030xexx991.htm — REPLIGEN CORP 8-K exhibit — SEC EDGAR
- Exhibit rgen-20261030xexx992.htm — REPLIGEN CORP 8-K exhibit — SEC EDGAR
- Repligen Announces $1 Billion Private Convertible Senior Notes Transaction — Yahoo Finance
- Repligen Announces $1 Billion Private Convertible Senior — globenewswire.com
More on Repligen
- Repligen Says BioLife Deal Puts 2027 Revenue Above $1 Billion, But Calls It Not Formal Guidance
- Repligen CEO Says Equipment 'Tap' Is Only 5-10% Open, Even After Five-Year High In Orders
- Repligen Lifts 2026 Revenue Outlook To $844 Million-$852 Million, Yet A $41.2 Million Writedown Drives A Quarterly Loss